Physician profile
Subrata Roy
NPI 1649278151
$3,316.23
in general payments reported to CMS, 2019-2025
14 companies · $587 in 2025
The $587 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $33.15 · 2021: $363 · 2022: $804 · 2023: $743 · 2024: $665 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.31 |
| Education | $117.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,074.86 | 2021-2025 | Vraylar |
| Alkermes, INC. | $490.15 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $397.12 | 2020-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $283.52 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $252.18 | 2022-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $235.32 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $178.63 | 2023-2025 | Uzedy, Austedo Xr |
| Indivior INC. | $170.27 | 2019-2024 | Sublocade, Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.12 | 2021-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $35.34 | 2022 | |
| Axsome Therapeutics, INC. | $35.12 | 2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $29.01 | 2021-2022 | |
| Lundbeck LLC | $12.43 | 2022 | |
| Noven Therapeutics, LLC | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subrata Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.